JOINN(603127)2024-07-10 09:07Revenue and Profit Expectations - Expected revenue for the first half of 2024 is between RMB 719.50 million and RMB 973.44 million, a decrease of RMB 38.64 million to RMB 292.58 million compared to the same period last year, representing a decline of 3.8% to 28.9%[7][8] - Revenue for the first half of 2024 is RMB 1,012.08 million[4] - Expected net profit attributable to shareholders for the first half of 2024 is between RMB -184.36 million and RMB -136.26 million, indicating a loss compared to the same period last year[7] - Expected net profit attributable to shareholders after deducting non-recurring gains and losses for the first half of 2024 is between RMB -220.60 million and RMB -163.05 million[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses for the first half of 2024 is RMB 76.89 million[4] - Earnings per share for the first half of 2024 is RMB 0.17[11] Business Segment Performance - Laboratory service business net profit for the first half of 2024 is expected to be between RMB -28.29 million and RMB 10.94 million[9] - Net profit from capital management is expected to contribute between RMB 49.60 million and RMB 54.82 million for the first half of 2024[9] Fair Value and Market Factors - Net loss from changes in the fair value of biological assets is expected to be between RMB 223.59 million and RMB 247.13 million for the first half of 2024[3] - The decline in revenue and net profit is attributed to reduced market demand, intensified competition, and a decrease in the fair value of biological assets[12][13]